

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT


(10) International Publication Number
WO 01/60315 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: **PCT/CA01/00197**
- (22) International Filing Date: 19 February 2001 (19.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/183,349 18 February 2000 (18.02.2000) US
- (71) Applicant (*for all designated States except US*): **BIOCHEM PHARMA INC. [CA/CA]; 275 Armand-Frappier, Laval, Québec H7V 4A7 (CA).**
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **ISMAILI, Hicham, Moulay, Alaoui [CA/CA]; 5059 Westmore, Montréal, Québec H4V 1Z4 (CA). CHENG, Yun-Xing [CA/CA]; 1 Davignon, Apt. 319, Dollard des Ormeaux, Québec H9B 2M4 (CA). LAVALLÉE, Jean-François [CA/CA]; 28 Chemin Scraire, Bellefeuille, Québec J0R 1A0 (CA). SIDDIQUI, Arshad [CA/CA]; 116 Stéphanie, Dollard des Ormeaux, Québec H9A 3B5 (CA). STORER, Richard [GB/CA]; 215 Oakridge, Baie d'Urfé, Québec H9X 2N3 (CA).**
- (74) Agents: **MURPHY, Kevin, P. Swabey Ogilvy Renault et al.; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).**
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/60315 A2

(54) Title: **METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS USING NUCLEOSIDE ANALOGUES**

(57) Abstract: The present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula (I) or a pharmaceutically acceptable salt thereof.

METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS
INFECTIONS USING NUCLEOSIDE ANALOGUES

FIELD OF THE INVENTION

The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues.

10 BACKGROUND OF THE INVENTION

Hepatitis is a disease occurring throughout the world. It is generally of viral nature, although there are other causes known. Viral hepatitis is by far the most common form of hepatitis. Nearly 750,000 Americans are affected by hepatitis each year, and out of those, more than 150,000 are infected with the hepatitis C virus (HCV).

HCV is a positive-stranded RNA virus belonging to the 20 *Flaviviridae* family and has closest relationship to the pestiviruses that include hog cholera virus and bovine viral diarrhea virus (BVDV). HCV is believed to replicate through the production of a complementary negative-strand RNA template. Due to the lack of an efficient culture replication system for the virus, HCV particles were isolated from pooled human plasma and shown, by electron microscopy, to have a diameter of about 50-60 nm. The HCV genome is a single-stranded, positive-sense RNA of about 9,600 bp coding for a polyprotein of 3009-3030 amino-30 acids, which is cleaved co- and post-translationally by cellular and two viral proteinases into mature viral proteins (core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). It is believed that the structural proteins, E1 and E2, the major glycoproteins are embedded into a viral lipid envelop and form stable heterodimers. It is also believed that the structural core protein interacts with

the viral RNA genome to form the nucleocapsid. The nonstructural proteins designated NS2 to NS5 include proteins with enzymatic functions involved in virus replication and protein processing including a polymerase, protease and helicase.


The main source of contamination with HCV is blood. The magnitude of the HCV infection as a health problem is illustrated by the prevalence among high-risk groups. For 10 example, 60% to 90% of hemophiliacs and more than 80% of intravenous drug abusers in western countries are chronically infected with HCV. For intravenous drug abusers, the prevalence varies from about 28% to 70% depending on the population studied. The proportion of new HCV infections associated with post-transfusion has been markedly reduced lately due to advances in diagnostic tools used to screen blood donors.

The only treatment currently available for HCV infection 20 is interferon- α (IFN- α). However, according to different clinical studies, only 70% of treated patients normalize alanine aminotransferase (ALT) levels in the serum and after discontinuation of IFN, 35% to 45% of these responders relapse. In general, only 20% to 25% of patients have long-term responses to IFN. Clinical studies have shown that combination treatment with IFN and ribavirin (RIBA) results in a superior clinical response than IFN alone. Different genotypes of HCV respond differently to IFN therapy, genotype 1b is more resistant 30 to IFN therapy than type 2 and 3.

There is therefore a great need for the further development of anti-viral agents.

Summary of the invention


The present invention relates to a method for the treatment or prevention of Flavivirus infections in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof:



wherein

10 **B** is chosen from a purine, a pyrimidine or an analogue thereof;

Ra is chosen from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, and



wherein each **Rc** are independently chosen from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl and an hydroxy protecting group; and

20 **Z** is halogen or **ORb**, wherein **Rb** is chosen from of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ acyl, or an hydroxy protecting group

D₁ and **D₂** are independently selected from N₃, F, or H, **D₁** and **D₂** can also be joined to be chosen from C₃-cycloalkyl, =CH₂, or =CF₂, and

wherein said compound is in the form of a single enantiomer or a mixture thereof including racemic mixtures;

with the proviso that when **B** is adenine, **Z** is **ORb**, **D₁** is **H**, **D₂** is **H** and **Rb** is **H**, **Ra** is not triphosphate or **H**.

In another aspect, there is provided a pharmaceutical formulation comprising the compounds of the invention in combination with a pharmaceutically acceptable carrier or excipient.

- 10 Still another aspect, there is provided a method for treating or preventing a viral infection in a host comprising administering a combination comprising at least one compound according to formula I and at least one further therapeutic agent.

In another aspect of the invention is the use of a compound according to formula I, for the preparation of a medicament for treating or preventing a viral infections in a host.

20

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the viral infection is chosen from *Flavivirus* infections.

In one embodiment, the *Flavivirus* infection is chosen from Hepatitis C virus (HCV), bovine viral diarrhea virus(BVDV), hog cholera virus and yellow fever virus.

30


In an other embodiment, the *Flavivirus* infection is Hepatitis C virus.

In one embodiment, there is also provided a method for inhibiting or reducing the activity of viral polymerase

in a host comprising administering a therapeutically effective amount of a compound having the formula I.

In another embodiment, the viral polymerase is HCV polymerase.

The present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a 10 therapeutically effective amount of a compound having the formula Ia or a pharmaceutically acceptable salt thereof:




(Ia)

wherein

B is chosen from a purine, a pyrimidine or an analogue thereof;

Ra is chosen from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, 20 C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, and



wherein each **Rc** are independently chosen from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl and an hydroxy protecting group; and

Z is halogen or **ORb**, wherein **Rb** is chosen from of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ acyl, or an hydroxy protecting group; and

wherein said compound is in the form of a single enantiomer or a mixture thereof including racemic mixtures;

with the proviso that when **B** is adenine, **Z** is **ORb** and **Rb** is H, **Ra** is not triphosphate or H.

In one embodiment, the compounds and methods of the present invention comprise those wherein the following embodiments are present, either independently or in
10 combination.

In one embodiment, **B** is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, 3-carboxamido-1,2,4-triazol-1-yl, 1-deaza-adenin-9-yl, 1-deaza-guanin-9-yl, 1-deaza-inosin-9-yl, 1-deaza-2-amino-purin-9-yl, 1-deaza-2-amino-6-chloro-purin-9-yl, 1-deaza-2-6-diamino-purin-9-yl, 3-deaza-adenin-9-yl, 3-deaza-guanin-9-yl, 3-deaza-inosin-9-yl, 3-deaza-2-amino-purin-9-yl, 3-deaza-2-amino-6-chloro-purin-9-yl 3-deaza-2-6-diamino-purin-9-yl, 7-deaza-adenin-9-yl, 7-deaza-guanin-9-yl, 7-deaza-inosin-9-yl, 7-deaza-2-amino-purin-9-yl, 7-deaza-2-amino-6-chloro-purin-9-yl, 7-deaza-2-6-diamino-purin-9-yl, 7-deaza-8-aza-adenin-9-yl, 7-deaza-8-aza-guanin-9-yl, 7-deaza-8-aza-inosin-9-yl, 7-deaza-8-aza-2-amino-purin-9-yl, 7-deaza-8-aza-2-amino-6-chloro-purin-9-yl, 7-deaza-8-aza-2-6-diamino-purin-9-yl, 8-aza-adenin-9-yl, 8-aza-guanin-9-yl, 8-aza-inosin-9-yl, 8-aza-2-amino-purin-9-yl, 8-aza-2-amino-6-chloro-purin-9-yl, 8-aza-2-6-diamino-purin-9-yl , 2-aza-adenin-9-yl, 2-aza-guanin-9-yl, 2-aza-inosin-9-yl, 2-aza-2-amino-purin-9-yl, 2-aza-2-amino-6-chloro-purin-9-yl, 2-aza-2-6-diamino-purin-9-yl, 3-deaza-thymin-1-yl, 3-deaza-cytosin-1-yl, 3-deaza-uracil-1-yl, 5-aza-thymin-1-yl, 5-aza-cytosin-1-yl, 5-aza-uracil-1-yl, 6-aza-thymin-1-yl, 6-aza-cytosin-1-yl, 6-aza-uracil-1-yl

each of which is unsubstituted or substituted by at least one of NHR_3 , $\text{C}_{1-6}\text{alkyl}$, $-\text{OC}_{1-6}\text{alkyl}$, Br , Cl , F , I or OH , wherein R_3 is H , $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{acyl}$.

In one embodiment, B is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, 3-carboxamido-1,2,4-triazol-1-yl, 3-deaza-adenin-9-yl, 3-deaza-guanin-9-yl, 3-deaza-inosin-9-yl, 3-deaza-2-amino-purin-9-yl, 3-deaza-2-amino-6-chloro-purin-9-yl, 3-deaza-2-6-diamino-purin-9-yl, 7-deaza-adenin-9-yl, 7-deaza-guanin-9-yl, 7-deaza-inosin-9-yl, 7-deaza-2-amino-purin-9-yl, 7-deaza-2-amino-6-chloro-purin-9-yl, 7-deaza-2-6-diamino-purin-9-yl, 7-deaza-8-aza-adenin-9-yl, 7-deaza-8-aza-guanin-9-yl, 7-deaza-8-aza-inosin-9-yl, 7-deaza-8-aza-2-amino-purin-9-yl, 7-deaza-8-aza-2-amino-6-chloro-purin-9-yl, 7-deaza-8-aza-2-6-diamino-purin-9-yl, 8-aza-adenin-9-yl, 8-aza-guanin-9-yl, 8-aza-inosin-9-yl, 8-aza-2-amino-purin-9-yl, 8-aza-2-amino-6-chloro-purin-9-yl, 8-aza-2-6-diamino-purin-9-yl, 2-aza-adenin-9-yl, 2-aza-guanin-9-yl, 2-aza-inosin-9-yl, 2-aza-2-amino-purin-9-yl, 2-aza-2-amino-6-chloro-purin-9-yl, 2-aza-2-6-diamino-purin-9-yl, 3-deaza-thymin-1-yl, 3-deaza-cytosin-1-yl, 3-deaza-uracil-1-yl, 5-aza-thymin-1-yl, 5-aza-cytosin-1-yl, 5-aza-uracil-1-yl, 6-aza-thymin-1-yl, 6-aza-cytosin-1-yl, 6-aza-uracil-1-yl each of which is unsubstituted or substituted by at least one of NHR_3 , $\text{C}_{1-6}\text{alkyl}$, $-\text{OC}_{1-6}\text{alkyl}$, Br , Cl , F , I or OH , wherein R_3 is H , $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{acyl}$.

30

In one embodiment, B is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, 3-carboxamido-1,2,4-triazol-1-yl, 3-deaza-adenin-9-yl, 3-deaza-guanin-9-yl, 3-deaza-inosin-9-yl, 3-deaza-2-amino-purin-9-yl, 3-deaza-2-amino-6-chloro-

purin-9-yl 3-deaza-2-6-diamino-purin-9-yl, 7-deaza-adenin-9-yl, 7-deaza-guanin-9-yl, 7-deaza-inosin-9-yl, 7-deaza-2-amino-purin-9-yl, 7-deaza-2-amino-6-chloro-purin-9-yl, 7-deaza-2-6-diamino-purin-9-yl, 7-deaza-8-aza-adenin-9-yl, 7-deaza-8-aza-guanin-9-yl, 7-deaza-8-aza-inosin-9-yl, 7-deaza-8-aza-2-amino-purin-9-yl, 7-deaza-8-aza-2-amino-6-chloro-purin-9-yl, 7-deaza-8-aza-2-6-diamino-purin-9-yl, 8-aza-adenin-9-yl, 8-aza-guanin-9-yl, 8-aza-inosin-9-yl, 8-aza-2-amino-purin-9-yl, 8-aza-2-6-diamino-purin-9-yl, 5-aza-thymin-1-yl, 5-aza-cytosin-1-yl, 5-aza-uracil-1-yl, 6-aza-thymin-1-yl, 6-aza-cytosin-1-yl, 6-aza-uracil-1-yl
10 each of which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, -OC₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

In one embodiment, B is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, 3-carboxamido-1,2,4-triazol-1-yl each of which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, -OC₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

In a further embodiment, B is chosen from adenin-9-yl, guanin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, each of which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, -OC₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

In a further embodiment, B is chosen from guanin-9-yl, cytosin-1-yl, uracil-1-yl, each of which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, -OC₁₋

alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

In a further embodiment, B is cytosin-1-yl, which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

10 In a further embodiment, B is guanin-9-yl, which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

In a further embodiment, B is uracil-1-yl, which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

20 In one embodiment, B is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, 5-fluoro-cytosin-1-yl, uracil-1-yl, 5-fluorouracil or 1,2,4-triazole-3-carboxamide base (ribarivin base).

In one embodiment, B is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, 5-fluoro-cytosin-1-yl, uracil-1-yl, or 1,2,4-triazole-3-carboxamide base (ribarivin base).

30 In one embodiment, B is chosen from guanin-9-yl, cytosin-1-yl, 5'-fluoro-cytosin-1-yl, 5'-fluorouracil -1-yl or uracil-1-yl.

In one embodiment, **B** is chosen from guanin-9-yl, cytosin-1-yl, 5'-fluoro-cytosin-1-yl, 5'-fluorouracil -1-yl or uracil-1-yl.

In one embodiment, **B** is cytosin-1-yl.

In one embodiment, **B** is 5-fluoro-cytosin-1-yl.


In one embodiment, **B** is 5-fluorouracil.

10

In one embodiment, **B** is guanin-9-yl.

In one embodiment, **B** is uracil-1-yl.

In a further embodiment, **B** is



Wherein;

- X** is H, halogen or NHR₁₀, wherein R₁₀ is H, C₁₋₆acyl, C₁₋₆alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl;
Y is H, halogen or NHR₁₁, wherein R₁₁ is H, C₁₋₆acyl, C₁₋₆alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl;
Y₂ is H, halogen or NHR₁₂, wherein R₁₂ is H, C₁₋₆acyl, C₁₋₆alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl;

R_9 is H, hydroxy protecting group, C_{1-6} acyl, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl;
 Y_3 is H, halogen or NHR_{13} , wherein R_{13} is H, C_{1-6} acyl, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl;
 R_7 is H, halogen, C_{1-6} acyl, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl;
 R_8 is H, halogen, C_{1-6} acyl, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl.

- 10 In one embodiment,
 X is H, halogen or NHR_{10} , wherein R_{10} is H.
 Y is H, halogen or NHR_{11} , wherein R_{11} is H.
 Y_2 is H, halogen or NHR_{12} , wherein R_{12} is H.
 R_9 is H, hydroxy protecting group, C_{1-6} alkyl.
 Y_3 is H, halogen or NHR_{13} , wherein R_{13} is H.
 R_7 is H, halogen, or C_{1-6} alkyl.
 R_8 is H, halogen or C_{1-6} alkyl.

- 20 In a further embodiment,
 X is H, F, or NHR_{10} , wherein R_{10} is H.
 Y is H, F, or NHR_{11} , wherein R_{11} is H.
 Y_2 is H, F, or NHR_{12} , wherein R_{12} is H.
 R_9 is H.
 Y_3 is H, F, or NHR_{13} , wherein R_{13} is H.
 R_7 is H, F, or C_{1-6} alkyl.
 R_8 is H, F, or C_{1-6} alkyl.

- In one embodiment of the invention, R_a is chosen from H,
30 monophosphate, diphosphate, and triphosphate.

In another embodiment of the invention, R_a is H.

In one embodiment, **Z** is F or **OR_b**, wherein **R_b** is chosen from of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ acyl, or an hydroxy protecting group.

In one embodiment, **Z** is F.

In one embodiment, **Z** is **OR_b**, wherein **R_b** is chosen from of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ acyl, or an hydroxy protecting group.

In one embodiment, **Z** is **OR_b**, wherein **R_b** is chosen from of H, C₁₋₆ alkyl, or an hydroxy protecting group.

- 10 In one embodiment, **Z** is **OR_b**, wherein **R_b** is chosen from of H, or methyl.

In one embodiment, **Z** is **OR_b**, wherein **R_b** is H.

D₁ and **D₂** are independently selected from N₃, F, or H , **D₁** and **D₂** can also be joined to be chosen from cyclopropyl, difluorocyclopropyl --CH₂, or --CF₂.

D₁ and **D₂** are independently selected from F, or H , **D₁** and **D₂** can also be joined to be chosen from cyclopropyl, difluorocyclopropyl --CH₂, or --CF₂.

- 20 **D₁** and **D₂** are joined and are cyclopropyl.

D₁ and **D₂** are joined and are difluorocyclopropyl.

D₁ and **D₂** are joined and are --CH₂.

D₁ and **D₂** are joined and are--CF₂.

In one embodiment, **D₁** is H or F.

In one embodiment, **D₂** is H or F.

In one embodiment, **D₁** is H.

In one embodiment, **D₂** is H.

In one embodiment, **D₁** is F.

In one embodiment, **D₂** is F.

- 30 In one embodiment, **D₁** is N₃ and **D₂** is H.

In one embodiment, **D₁** is H and **D₂** is N₃.

In one embodiment, **D₁** is N₃ and **D₂** is F.

In one embodiment, **D₁** is F and **D₂** is N₃.


In one embodiment, **D₁** is H and **D₂** is F.

In one embodiment, D_1 is F and D_2 is H.

In one embodiment, D_1 and D_2 are H.


In one embodiment, D_1 and D_2 are F.

- In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula Ib or a pharmaceutically acceptable salt thereof:
- 10




wherein **Ra**, **B**, **D₁**, **D₂** and **Z** are as defined above.

- In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula Ic or a pharmaceutically acceptable salt thereof:
- 20




wherein **Ra**, **B**, **D₁**, **D₂** and **Z** are as defined above.

In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula Id or a pharmaceutically acceptable salt thereof:




10 wherein Ra, B, D₁, D₂ and Z are as defined above.

In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula Ie or a pharmaceutically acceptable salt thereof:



20 wherein Ra, B, D₁, D₂ and Z are as defined above.


In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula If or a pharmaceutically acceptable salt thereof:



(If)

wherein Ra, B, and Z are as defined above.


In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula Ig or a 10 pharmaceutically acceptable salt thereof:



(Ig)

wherein Ra, B, and Z are as defined above.


In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula Ih or a 20 pharmaceutically acceptable salt thereof:



(Ih)

wherein **R_a**, **B**, and **Z** are as defined above.

In a further embodiment, the present invention relates to a method for the treatment or prevention of *Flavivirus* infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula II or a pharmaceutically acceptable salt thereof:



10

(II)

wherein **R_a**, **B**, and **Z** are as defined above.

In one embodiment, a compound of formula (I) is chosen from:

3'-deoxycytidine Z=H, Compound #1, 3'-deoxycytidine- 5'triphosphate Z=triphosphate, Compound #2	
5-Fluoro-3'-deoxycytidine Z=H, Compound #3 5-Fluoro-3'-deoxycytidine- 5'triphosphate Z=triphosphate, Compound #4	

<p>3'-deoxyuridine Z=H, Compound #5</p> <p>3'-deoxyuridine- 5' triphosphate Z=triphasphate, Compound #6</p>	
<p>5-Fluoro-3'-deoxyuridine Z=H, Compound #7</p> <p>5-Fluoro-3'-deoxyuridine- 5' triphosphate Z=triphasphate, Compound #8</p>	
<p>3'-deoxythymidine Z=H, Compound #9</p> <p>3'-deoxythymidine- 5' triphosphate Z=triphasphate, Compound #10</p>	
<p>3'-deoxyguanosine Z=H, Compound #11</p> <p>3'-deoxyguanosine- 5' triphosphate Z=triphasphate, Compound #12</p>	


<p>2-N-acetyl-3'-deoxyguanosine Z=H, Compound #13</p> <p>2-N-acetyl-3'-deoxyguanosine- 5' triphosphate Z=triphosphate, Compound #14</p>	
<p>5-Methyl-3'-deoxycytidine Z=H, Compound #15,</p> <p>5-Methyl-3'-deoxycytidine- 5' triphosphate Z=triphosphate, Compound #16</p>	
<p>5-Iodo-3'-deoxycytidine Z=H, Compound #17,</p> <p>5-Iodo-3'-deoxycytidine- 5' triphosphate Z=triphosphate, Compound #18</p>	
<p>5-Chloro-3'-deoxycytidine Z=H, Compound #19,</p> <p>5-Chloro-3'-deoxycytidine- 5' triphosphate Z=triphosphate, Compound #20</p>	

<p>3'-fluoro-3'-deoxyguanosine Z=H, Compound #21</p> <p>3'-fluoro-3'-deoxyguanosine - 5' triphosphate Z=triposphate, Compound #22</p>	
<p>3'-fluoro 3'-deoxycytidine Z=H, Compound #23,</p> <p>3'-fluoro 3'-deoxycytidine- 5' triphosphate Z=triposphate, Compound #24</p>	
<p>5-Iodo-3'-deoxycytidine Z=H, Compound #25,</p> <p>5-Iodp-3'-deoxycytidine- 5' triphosphate Z=triposphate, Compound #26</p>	
<p>5-Chloro -3'-deoxyuridine Z=H, Compound #27</p> <p>5-Chloro -3'-deoxyuridine- 5' triphosphate Z=triposphate, Compound #28</p>	

<p>5-Bromo -3'-deoxyuridine Z=H, Compound #29</p> <p>5-Bromo -3'-deoxyuridine- 5' triphosphate Z=triposphate, Compound #30</p>	
<p>6-Chloro-3'-deoxyguanosine Z=H, Compound #31</p> <p>6-Chloro -3'-deoxyguanosine - 5' triphosphate Z=triposphate, Compound #32</p>	
<p>3'-spirocyclopropyl-3'- deoxyguanosine Z=H, Compound #33</p> <p>3'-spirocyclopropyl-3'- deoxyguanosine 5' triphosphate Z=triposphate, Compound #34</p>	
<p>3'-difluoro-spirocyclopropyl- 3'-deoxyguanosine Z=H, Compound #35</p> <p>3' - difluoro- spirocyclopropyl-3'- deoxyguanosine 5' triphosphate Z=triposphate, Compound #36</p>	

<p>3'-methylene-3'- deoxyguanosine Z=H, Compound #37</p>	
<p>3'-methylene-3'- deoxyguanosine 5'triphosphate Z=triphosphate, Compound #38</p>	
<p>3'-difluoromethylene 3'- deoxyguanosine Z=H, Compound #39</p>	
<p>3'-difluoromethylene 3'- deoxyguanosine 5'triphosphate Z=triphosphate, Compound #40</p>	
<p>3'-spirocyclopropyl-3'- deoxycytidine Z=H, Compound #41</p>	
<p>3'-spirocyclopropyl-3'- deoxycytidine -5'triphosphate Z=triphosphate, Compound #42</p>	
<p>3'-difluoro-spirocyclopropyl- 3'- deoxycytidine Z=H, Compound #43</p>	
<p>3'- difluoro- spirocyclopropyl-3'-</p>	

deoxycytidine -5' triphosphate Z=triposphate, Compound #44	
3'-methylene-3'- deoxycytidine Z=H, Compound #45	
3'-methylene-3'- deoxycytidine -5' triphosphate Z=triposphate, Compound #46	
3'-difluoromethylene 3'- deoxycytidine Z=H, Compound #47	
3'-difluoromethylene 3'- deoxycytidine -5' triphosphate Z=triposphate, Compound #48	
9-β-D-xylofuranosyl-guanosine Z=H, Compound #49	
9-β-D-xylofuranosyl-guanosine -5' triphosphate Z=triposphate, Compound #50	
9-β-D-xylofuranosyl-cytidine Z=H, Compound #51	
9-β-D-xylofuranosyl-cytidine -5' triphosphate Z=triposphate, Compound #52	



It will be appreciated by those skilled in the art that the compounds of formula (I) contain at least three chiral centres and which are marked by 1, 2 and 3. When D1 and D2 are different, the compounds of formula (I) contain at least four chiral centres which are marked by 1, 2, 3 and 4. The compounds of formula (I) thus exist in the form of different optical isomers (e.g. β -L and β -D) and geometric isomers trans or α and cis or β . All such enantiomers, geometric isomers and mixtures thereof including racemic mixtures are included within the scope of the invention. The single optical isomer or enantiomer can be obtained by method well known in the art, such as chiral HPLC, enzymatic resolution and the use of chiral auxiliary.

According to one embodiment, the atoms marked by 1 and 2 are in the cis or β configuration.

20 According to one embodiment, the atoms marked by 1 and 2 are in the cis or β configuration while the atom marked by 3 is in a trans or α configuration with respect to the atom 1 and 2.

According to one embodiment, compounds of formula I of the present invention are provided substantially in the form of the β -D configuration.

According to one embodiment, compounds of formula I of the present invention are provided substantially in the form of the β -L configuration.

By "substantially" is meant that there is more one enantiomer than of the other enantiomer.

In another embodiment, the compounds of formula I of the present invention are at least 95% free of the
10 corresponding β -D enantiomer.

In another embodiment, the compounds of formula I of the present invention are at least 97% free of the corresponding β -D enantiomer.

Still in another embodiment, the compounds of formula I of the present invention are at least 99% free of the corresponding β -D enantiomer.

20 In another embodiment, the compounds of formula I of the present invention are at least 95% free of the corresponding β -L enantiomer.

In another embodiment, the compounds of formula I of the present invention are at least 97% free of the corresponding β -L enantiomer.

Still in another embodiment, the compounds of formula I of the present invention are at least 99% free of the
30 corresponding β -L enantiomer.

There is also provided pharmaceutically acceptable salts of the compounds of formula I of the present invention. By the term pharmaceutically acceptable salts of the compounds of formula (I) are meant those derived from

pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids.

- 10 Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and NR₄⁺ (where R is C₁₋₄ alkyl) salts.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

- 20 In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

As used in the present application, "compound(s) of formula (I)" refers to all compounds identified by formula (I) and formulae (Ia) to (Ii).

- As used in this application, the term "purine or pyrimidine or an analogue thereof" is meant a purine or pyrimidine base found in nucleotide or an analogue thereof which mimics such bases in that their structures (the kinds of atoms and their arrangement) are similar to the normal bases but may possess additional or lack certain of the functional properties of the normal bases. Such analogues include those derived by replacement of a

CH moiety by a nitrogen atom (for example, 5-azapyrimidines such as 5-azacytosine) or vice versa (for example 7-deazapurines, such as 7-deazadenosine or 7-deazaguanosine) or both (e.g. 7-deaza, 8-azapurines). Analogues of such bases also include those compounds wherein ring substituents are either incorporated, removed or modified by conventional substituents known in the art e.g. halogen, hydroxyl, amino, C₁-6 alkyl. Such purine or pyrimidine base, analogues and derivatives will 10 be well known to those skilled in the art.

As used in this application, the term "alkyl" represents an unsubstituted or substituted (by a halogen, nitro, CONH₂, COOH, O-C₁-6 alkyl, O-C₂-6 alkenyl, O-C₂-6 alkynyl, hydroxyl, amino, or COOQ, wherein Q is C₁-6 alkyl; C₂-6 alkenyl; C₂-6 alkynyl) straight chain, branched chain or cyclic hydrocarbon moiety (e.g. isopropyl, ethyl, fluorohexyl or cyclopropyl). The term alkyl is also meant to include alkyls in which one or more hydrogen atoms is replaced by an halogen, more preferably, the halogen is fluoro (e.g. CF₃- or CF₃CH₂-). 20

As used in this application, the term "cycloalkyl" represents an "alkyl" as defined above which forms a ring.

The terms "alkenyl" and "alkynyl" represent an alkyl containing at least one unsaturated group (e.g. allyl).

30 The term "hydroxy protecting group" is well known in the field of organic chemistry. Such protecting groups may be found in T. Greene, Protective Groups In Organic Synthesis, (John Wiley & Sons, 1981). Example of hydroxy protecting groups include but are not limited to acetyl-2-thioethyl ester, pivaloyloxymethyl ester and isopropyloxycarbonyloxymethyl ester.

The term "aryl" represents an unsaturated carbocyclic moiety, optionally mono- or di-substituted with OH, SH, amino, halogen or C₁₋₆ alkyl.

The term "heteroaryl" represents an aryl wherein at least one carbon ring atom is substituted by an heteroatom (e.g. N, O, or S).

10 The term "aminoalkyl" represents an alkyl which is covalently bonded to the adjacent atom through a nitrogen atom.

The term "thioalkyl" represents an alkyl which is covalently bonded to the adjacent atom through a sulfur atom.

The term "alkoxy" represents an alkyl which is covalently bonded to the adjacent atom through an oxygen atom.

20 Halogen are chosen from F, Cl, I, and Br.

The term "host" represents any mammals including humans.

In one embodiment, the host is human.

The compounds of the present invention are can be prepared by methods well known in the art. For example, such methods are described in the following references J.Med.Chem. 1991, 34, 693-701; Chem. Pharm. Bull. 1995, 30 43(11) 2005-2009; J.Org.Chem. 1989, 54, 631-635; Can.J.Chem. 1975, 53(19), 2975-2977; Nucleosides Nucleotides, 1990, 9(8), 1045-60 and Chemistry of Nucleosides and Nucleotides edited by Leroy B.Towsend, 1988 Plenum Press Volumes 1 and 2; Synthesis of 2'- β -fluoro- and 3'- β -fluoro-substituted guanine nucleosides.

Effect of sugar conformational shifts on nucleophilic displacement of the 2'-hydroxy and 3'-hydroxy group with DAST. J. Org. Chem. , 57(26), (1992) 7315-21. Synthesis and antiviral and cytostatic properties of 3'-deoxy-3'-fluoro- and 2'-azido-3'-fluoro-2',3'-dideoxy-D-ribofuranosides of natural heterocyclic bases. J. Med. Chem. , 34(7), (1991) 2195-202. Synthesis of 9-(3-deoxy-3-fluoro- β -D-ribofuranosyl)guanine, a new potent antiviral agent. J. Chem. Soc., Chem. Commun. (1989) 10 (14), 955-7. Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of 3'-fluoro-3'-deoxyadenosine. Antiviral Res. (1989), 12(3), 133-50. 3'-Fluoro-3'-deoxyribonucleoside 5'-triphosphates: synthesis and use as terminators of RNA biosynthesis. FEBS Lett. (1989), 250(2), 139-41. Reaction of 1-(2',3'-epoxy- β -D-lyxofuranosyl)uracil with hydrogen fluoride. The unexpected formation of 1-(3'-fluoro-3'-deoxy- β -D-ribofuranosyl)uracil. J. Heterocycl. Chem. (1984), 21(3), 20 773-5. Synthesis of 3'-deoxy-3'-fluorouridine. J. Carbohydr., Nucleosides, Nucleotides (1975), 2(3), 191-5. Synthesis of the 2'-deoxy-2'-fluoro and 3'-deoxy-3'-fluoro analogs of 8-bromoadenosine. Nucleic Acids Symp. Ser. (1997), 37(Symposium on Nucleic Acids Chemistry, 1997), 17-18. Synthesis of 8-substituted analogs of 3'-deoxy-3'-fluoroadenosine. Nucleosides Nucleotides (1998), 17(1-3), 115-122. A new synthesis of 3'-fluoro-3'-deoxyadenosine. Nucleosides Nucleotides (1991), 10(1-3), 719-21. Synthesis of 3'-fluoro-3'-deoxyadenosine starting from adenosine. Synthesis (1990), (10), 900-5. Synthesis of 3'-deoxy-3'-fluoroadenosine by chemical transglycosidation. Z. Chem. (1989), 29(6), 209-10. Stereoselective synthesis of 3'-deoxy-3'-fluoroadenosine. Bull. Chem. Soc. Jpn. (1989), 62(6), 2119-20. Synthesis of nucleosides fluorinated in the sugar moiety. The 30

application of diethylaminosulfur trifluoride to the synthesis of fluorinated nucleosides. Nucleosides Nucleotides (1989), 8(1), 65-96. Preparation of difluorouridines as antitumor agents. Efficient removal of sugar O-tosyl groups and heterocycle halogens from purine nucleosides with sodium naphthalenide. Tetrahedron (1997), 53(18), 6295-6302. Synthesis of fluoro and azido derivatives of purine nucleosides from nucleoside 2',3'-cyclic sulfates. Bioorg. Khim. (1994), 20(11), 1226-30.

10 Synthesis of modified oligomeric 2'-5' A analogs: potential antiviral agents. Helv. Chim. Acta (1991), 74(1), 7-23. Diethylaminosulfur trifluoride (DAST) as a fluorinating agent of pyrimidine nucleosides having a 2',3'-vicinal diol system. Chem. Pharm. Bull. (1990), 38(5), 1136-9. Synthesis of 9-(3-deoxy- and 2,3-dideoxy-3-fluoro- β -D-xylofuranosyl)guanines as potential antiviral agents. Tetrahedron Lett. (1989), 30(24), 3171-4.

20 Synthesis and anti-HIV activity of various 2'- and 3'-substituted 2',3'-dideoxyadenosines: a structure-activity analysis. J. Med. Chem. (1987), 30(11), 2131-7. Adenosine 2',3'-ribo-epoxide. Synthesis, intramolecular degradation, and transformation into 3'-substituted xylofuranosyl nucleosides and the lyxo-epoxide. J. Org. Chem. (1974), 39(11), 1564-70. Fluoro sugar analogs of arabinosyl- and xylosylcytosines. J. Med. Chem. (1970), 13(2), 269-72. 9-(3-Deoxy-3-fluoro- β -D-xylofuranosyl)adenine and 9-(3-deoxy-3-fluoro- β -D-arabinofuranosyl)adenine. Carbohydr. Res. (1968), 6(3), 347-54.

30 3',3'-Difluoro-3'-deoxythymidine: comparison of anti-HIV activity to 3'-fluoro-3'-deoxythymidine. J. Med. Chem. (1992), 35(18), 3369-72. Nucleic acid related compounds. 83. Synthesis of 3'-deoxyadenosine-3'-spirocyclopropane, 3'-deoxyuridine-3'-spirocyclopropane, and 5'-deoxy-4',5'-methanoadenosine. Tetrahedron Lett. (1994), 35(21), 3445-8. Synthesis of 2',3'-didehydro-

2',3'-dideoxy-3'-C-methyl substituted nucleosides. Nucleosides Nucleotides (1993), 12(8), 865-77. 2',3'-Didehydro-2',3'-dideoxy-2' (and 3')-methyl nucleosides via [3,3]-sigmatropic rearrangements of 2' (and 3')-methylene-3' (and 2')-O-thiocarbonyl derivatives and radical reduction of a 2'-chloro-3'-methylene analog. Can. J. Chem. (1993), 71(2), 186-91. Synthesis and biological activity of 2' (and 3')-deoxy-2' (and 3')-methylenenucleoside analogs that function as mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase and/or ribonucleotide reductase. J. Med. Chem. (1992), 35(12), 2283-93. Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogs and crystal structure of 2'-deoxy-2'-methylidene cytidine hydrochloride. J. Med. Chem. (1991), 34(8), 2607-15. Stereoselective addition of a Wittig reagent to give a single nucleoside oxaphospetane diastereoisomer. Synthesis of 2' (and 3')-deoxy-2' (and 3')-methyleneuridine (and cytidine) derivatives from uridine ketonucleosides. Synthesis (1991), (4), 282-8. A novel example of unsaturated branched chain sugar nucleoside: 3'-deoxy-3'-methylidene adenosine. Helv. Chim. Acta (1981), 64(2), 425-9. Synthesis of 2' (and 3')-deoxy-2' (and 3')-methylene adenosines and bis(methylene)furan 4',5'-didehydro-5'-deoxy-2' (and 3')-methylene adenosines. Inhibitors of S-adenosyl-L-homocysteine hydrolase and ribonucleotide reductase. J. Org. Chem. (1991), 56(25), 7108-13. Radical and palladium-catalyzed deoxygenation of the allylic alcohol systems in the sugar moiety of pyrimidine nucleosides. Nucleosides Nucleotides (1992), 11(2-4), 197-226. Synthesis and NMR spectra of some new carbohydrate modified uridine phosphoramidites. Nucleosides Nucleotides (1997), 16(7-9), 1529-1532. New method for the preparation of 3'- and 2'-phosphoramidites of 2'- and 3'-difluoromethyleneuridine. Tetrahedron

(1996), 52(23), 7929-7938. Nucleic acid related compounds. 83. Synthesis of 3'-deoxyadenosine-3'-spirocyclopropane, 3'-deoxyuridine-3'-spirocyclopropane, and 5'-deoxy-4',5'-methanoadenosine. Some compounds of the present invention are commercially available at Sigma or Aldrich.

According to one embodiment, it will be appreciated that the amount of a compound of formula I of the present 10 invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.01 to about 750 mg/kg of body weight per day, preferably in the range of 0.5 to 60 mg/kg/day, most preferably in the range of 1 to 20 mg/kg/day.

20

The desired dose according to one embodiment is conveniently presented in a single dose or as divided dose administered at appropriate intervals, for example as two, three, four or more doses per day.

30

In another embodiment, the compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active ingredient per unit dosage form.

According to another embodiment of the present invention, the active ingredient is administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 μ M, preferably about 2 to 50 μ M, most preferably about 3 to about 30 μ M. This may be achieved,

for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

- 10 While it is possible that, for use in therapy, a compound of formula I of the present invention may be administered as the raw chemical, it is preferable according to one embodiment of the invention, to present the active ingredient as a pharmaceutical formulation. The embodiment of the invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be 20 "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

According to one embodiment of the present invention, pharmaceutical formulations include but are not limited to those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including intramuscular, sub-cutaneous and 30 intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods according to this embodiment include the step of bringing into association the active compound with liquid

carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

According to another embodiment, pharmaceutical formulation suitable for oral administration are conveniently presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules. In another embodiment, the formulation is presented as a solution, a suspension or as an emulsion. Still in another embodiment, the active ingredient is presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

The compounds of formula I according to an embodiment of the present invention are formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing an/or dispersing agents.

Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

For topical administration to the epidermis, the compounds of formula I, according to one embodiment of the present invention, are formulated as ointments, 10 creams or lotions, or as a transdermal patch. Such transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

20 Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Pharmaceutical formulations suitable for rectal 30 administration wherein the carrier is a solid. In another embodiment, they are presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds.

According to one embodiment, the formulations suitable for vaginal administration are presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

For intra-nasal administration the compounds, in one embodiment of the invention, are used as a liquid spray 10 or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents, solubilising agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.

For administration by inhalation the compounds, according to one embodiment of the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol 20 spray. In another embodiment, pressurized packs comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In another embodiment, the dosage unit in the pressurized aerosol is determined by providing a valve to deliver a metered amount.

Alternatively, in another embodiment, for administration by inhalation or insufflation, the compounds of formula I according to the present invention are in the form of a 30 dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. In another embodiment, the powder composition is presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

In one embodiment, the above described formulations are adapted to give sustained release of the active ingredient.

The compounds of the invention may also be used in combination with other antiviral agents.

In one embodiment, the compounds of the invention may be 10 employed together with at least one other antiviral agent chosen from protease inhibitors, polymerase inhibitors, and helicase inhibitors.

As used in this application, the term "interferon" include: interferon like molecules such as interferon (IFN), interferon α -2a, interferon α -2b, consensus interferon (CIFN) and other types of interferons.

In one embodiment , the compounds of the invention may be 20 employed together with at least one other antiviral agent chosen from interferon (IFN), interferon α -2a, interferon α -2b, consensus interferon (CIFN), ribavirin, amantadine, rimantadine, interleukine-12, ursodeoxycholic acid (UDCA), glycyrrhizin and silybum marianum.

In one embodiment, the compounds of the invention may be employed together with at least one other antiviral agent chosen from Interferon- α , Ribavirin and Amantadine.

30 In one embodiment, the compounds of the invention may be employed together with at least one other antiviral agent chosen from Interferon- α and Ribavirin (REBETRON) .

In one embodiment, the compounds of the invention may be employed together Interferon- α .

In one embodiment, the compounds of the invention may be employed together with Ribavirin.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefor comprise a further aspect of the invention.


10 The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When the compound (I) or a pharmaceutically acceptable salts thereof is used in combination with a second therapeutic agent active against the same virus the dose of each compound may be either the same as or differ from 20 that when the compound is used alone.

Appropriate doses will be readily appreciated by those skilled in the art.

The following examples are provided to illustrate various embodiments of the present invention and shall not be considered as limiting in scope.

Example 1. Preparation of 3'-DEOXYCYTIDINE 5'-TRIPHOSPHATE TRIAMMONIUM SALT (Compound #2)



Procedure: To a stirring suspension of 3'-deoxy-2'-acetoxyctydine (15.0 mg, 0.056 mmol) in dry DMF (0.60 ml) was added dry pyridine (0.20 ml) followed by a freshly prepared solution of 2-chloro-4 H-1,3,2-benzodioxaphosphorin-4-one 0.5 M in 1,4-dioxane (111 μ l, 0.056 mmol). The mixture was stirred 30 minutes at room temperature, then tributylamine (36 μ l, 0.152 mmol) and a solution of tributylammonium pyrophosphate 0.5 M in DMF (101 μ l, 0.051 mmol) were added simultaneously. The 10 mixture was stirred another 30 minutes. A solution of I2 1% in pyridine/H₂O (98 :2) (1.01 ml, 0.081 mmol of I) was added and the mixture was stirred 30 minutes. The excess of iodine was destroyed by adding 0.2 ml of aqueous sodium bisulfite 5%. The mixture was stirred 15 minutes, then it was concentrated under reduced pressure to remove all solvents. The residue was dissolved in water, washed two times with methylene chloride and once with ethyl acetate. The aqueous layer was concentrated and purified by charcoal column as follow: about 400 mg of charcoal, 20 placed over a thin layer of Celite in a funnel with fritted disk, was prewashed by passing methanol, then deionized water (by vacuum). The crude residue was diluted in a minimum of water, acidified to pH 1-2 by adding few drops of HCl 1N, then placed on the top of the charcoal column. The column was eluted with deionized water (35 ml) in order to remove inorganic salts, then 0.5 N ammonia (15 ml) to collect the desired triphosphate. The collected triphosphate was concentrated and diluted in deionized water (1 ml) and concentrated 30 NH₄OH (2 ml). The mixture was stirred one hour at room temperature to cleave the acetyl group, then concentrated to dryness. The residue was purified on a pad of C18 RP silica gel eluting with deionized water (the desired triphosphate comes out fast). The fractions containing the desired triphosphate were collected and lyophilized.

to give the 3'-deoxycytidine 5'-triphosphate triammonium salt as a yellowish solid (18 mg, 69% yield, purity >85% evaluated by ^1H and ^{31}P -NMR). ^1H NMR (400 MHz, D₂O) δ : 7.90 (d, 1 H, 7.5 Hz), 5.99 (d, 1 H, 7.5 Hz), 5.73 (s, 1 H), 4.55 (s, 1 H), 4.35 (d, 1 H, 5.0 Hz), 4.26 (m, 1 H), 4.04 (m, 1 H), 2.05 (m, 1 H), 1.94 (m, 1 H) ppm. ^{31}P NMR (162 MHz, D₂O) δ : -5.9 (br.s), -10.4 (d, 19 Hz), -21.5 (br.s) ppm. In a similar manner, the compounds of the invention can be obtained.

10

Example 2. Evaluation of Triphosphate Analogues

In The HCV RNA-Dependent RNA Polymerase Assay The following references which are referenced in the example are all incorporated by reference:

1. Behrens, S., Tomei, L., De Francesco, R. (1996) EMBO 15, 12-22
2. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual. Cold Spring Harbord Laboratory. Cold Spring Harbord. NY.
- 20 3. Lohmann, V., Körner, F., Herian, U., and Bartenschlager, R. (1997) J. Virol. 71, 8416-8428

Compounds were evaluated using an *in vitro* polymerase assay containing purified recombinant HCV RNA-dependent RNA polymerase (NS5B protein). HCV NS5B was expressed in insect cells using a recombinant baculovirus as vector. The experimental procedures used for the cloning, expression and purification of the HCV NS5B protein are described below. Following are details of the RNA-dependent RNA polymerase assays used to test the compounds.

Expression of the HCV NS5B protein in insect cells:

The cDNA encoding the entire NS5B protein of HCV-Bk strain, genotype 1b, was amplified by PCR using a plasmid

containing a cDNA version of the full-length HCV genome as template. The oligonucleotides used to amplify this HCV region were designed to introduce a *NheI* site followed by an ATG at the 5' end of the NS5B coding region as well as a *BamHI* site at the 3'end immediately downstream of the translation stop codon. The amplified sequence, of 1.8 kb, was digested with *NheI* and *BamHI* and ligated to a predigested pBlueBacII plasmid (Invitrogen). The resulting recombinant plasmid was designated
10 pBac/NS5B. Sf9 cells were co-transfected with 3 µg of pBac/NS5B, together with 1 µg of linearized baculovirus DNA (Invitrogen), as described in the manufacturer's protocol. Following two rounds of plaque purification, an NS5B-recombinant baculovirus, BacNS5B, was isolated. The presence of the recombinant NS5B protein was determined by western blot analysis (Harlow and Lane, 1988) of BacNS5B-infected Sf9 cells, using a HCV NS5B specific rabbit polyclonal antiserum (anti-NS5B). Infections of Sf9 cells with this plaque purified virus were performed
20 in one-liter spinner flasks at a cell density of 1.2 x 10⁶ cells/ml and a multiplicity of infection of 5.

Preparation of a soluble recombinant NS5B protein:

Sf9 cells were infected as described above. Sixty hours post-infection, cells were harvested then washed twice with phosphate buffer saline (PBS). Total proteins were solubilized as described in Lohmann et al. (1989) with some modifications. In brief, proteins were extracted in
30 three steps, S1, S2, S3, using lysis buffers (LB) I, LB II and LB III (Lohmann et al, 1997). The composition of LBII was modified to contain 0.1 % triton X-100 and 150 mM NaCl to reduce the amount of solubilized NS5B protein at this step. In addition, sonication of cell extracts was avoided throughout the protocol to preserve the integrity of the protein structure.

Purification of recombinant NS5B using fast protein liquid chromatography (FPLC):

Soluble NS5B protein in the S3 fraction was diluted to lower the NaCl concentration to 300 mM, then it incubated batchwise with DEAE sepharose beads (Amersham-Pharmacia) for 2 hrs at 4°C, as described by Behrens et al. (1989). Unbound material was cleared by centrifugation for 15 min at 4°C, at 25 000 rpm using a SW41 rotor (Beckman). The supernatant was further diluted to lower the NaCl concentration to 200 mM and subsequently loaded, with a flow rate of 1 ml/min, on a 5 ml HiTrap® heparin column (Amersham-Pharmacia) connected to an FPLC® system (Amersham-Pharmacia). Bound proteins were eluted in 1 ml fractions, using a continuous NaCl gradient of 0.2 to 1 M, over a 25 ml volume. NS5B-containing fractions were identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by western blotting using the anti-NS5B antiserum at a dilution of 1:2000.

Positive fractions were pooled and the elution buffer was exchanged against a 50 mM NaPO₄ pH 7.0, 20 % glycerol, 0.5 % triton X-100 and 10 mM DTT, using a PD-10 column (Amersham-Pharmacia). The sample was then loaded onto a 1 ml HiTrap® SP column (Amersham-Pharmacia), with a flow rate of 0.1 ml/min. Bound proteins were eluted using a continuous 0 to 1 M NaCl gradient over a 15 ml volume. Eluted fractions were analyzed by SDS-PAGE and western blotting. Alternatively, proteins were visualized, following SDS-PAGE, by silver staining using the Silver Stain Plus kit (BioRad) as described by the manufacturer.

Positive fractions were tested for RdRp activity (see below) and the most active ones were pooled, and stored as a 40 % glycerol solution at -70°C.

In vitro RNA-dependent RNA polymerase assays used to evaluate the triphosphate form of nucleoside analogues:

RdRp assays were conducted using *in vitro* transcribed heteropolymeric RNA templates.

RdRp reactions were performed in a total volume of 50 μ l of a buffer consisting of 20 mM Tris-HCl pH 7.5, 1 mM DTT, 50 mM NaCl, 0.5 mM MnCl₂ and 5 mM MgCl₂. Standard HCV RdRp reactions contained 200 ng of purified NS5B protein. The substrate mixture included in the assay depended on the base of the nucleoside triphosphate to be tested (adenine, guanine, cytosine or uracil analogue).

10 The NTP substrate with a similar base to that of the inhibitor, was added at twice the measured Km. This concentration included 5 μ Ci (3000 Ci/mmol) of a [³²P] version of this nucleotide. The remaining three substrates were used at 100 μ M. The measured Kms for the four substrates were as follows: 18 μ M for ATP, 0.5 μ M for CTP and GTP, and 1.2 μ M for UTP. Following a two hour incubation at 22°C, reactions were stopped by the addition of 100 μ g of sonicated salmon sperm DNA (Life Technologies) and 1 ml of 10 % trichloroacetic acid (TCA)-0.5 % tetrasodium pyrophosphate (PPi). Nucleic acids were precipitated at 4°C for 30 min after which samples were filtered on GF/C glass microfiber filters (Millipore). Membranes were subsequently washed with 25 ml of a 1% TCA-0.1 % PPi solution, then air dried. Incorporated radioactivity was quantified using a liquid scintillation counter (1450-Microbeta, Wallac).

Heteropolymeric RNA templates were generated by run-off transcription. As template for these transcription reactions, a recombinant pcDNA3 plasmid (Invitrogen) 30 containing a cDNA version of the HCV genome was used and referred to as pcDNA/HCVf1. In vitro transcriptions were performed using the MEGAscript™ kit (Ambion), as suggested by the manufacturer. In brief, the plasmid pcDNA/HCVf1 was linearized with EcoRI to generate a truncated HCV transcript of about 6900 nucleotides. Linearized DNA was extracted with a one to one volume of


phenol/chloroform, precipitated with ethanol, then 1 µg of this linearized DNA was used as template in T7 RNA polymerase-driven in vitro transcription reactions. Transcripts were extracted using the TRIZOL® reagent (Life Technologies) and an aliquot (1 µg) was used as template in RdRp assays.

Compound	HCV polymerase
	IC ₅₀
COMPOUND#2	0.036µM
COMPOUND#4	0.3µM
COMPOUND#6	0.26µM
COMPOUND#8	1.98µM
COMPOUND#10	6.4µM
COMPOUND#12	0.048µM
COMPOUND#14	3.1µM
COMPOUND#16	0.36µM
COMPOUND#18	6.88µM
COMPOUND#20	0.18µM
COMPOUND#22	0.12µM
COMPOUND#24	0.055µM
COMPOUND#26	0.91µM
COMPOUND#28	2.1µM
COMPOUND#30	2.9µM
COMPOUND#32	6.8µM
COMPOUND#54	9.0µM

CLAIMS

We claim:

1. A method for the treatment or prevention of an hepatitis C infection in a host comprising administering a therapeutically effective amount of a compound having the formula Ib or a pharmaceutically acceptable salt thereof:




10

wherein

B is chosen from a purine, a pyrimidine or an analogue thereof;

Ra is chosen from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, and



wherein each **Rc** are independently chosen from H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl and an hydroxy protecting group; and

20 **Z** is **ORb**, wherein **Rb** is chosen from of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ acyl, or an hydroxy protecting group

D₁ and **D**₂ are independently selected from N₃, F, or H , **D**₁ and **D**₂ can also be joined to be chosen from C₃-cycloalkyl, --CH₂, or --CF₃;

with the proviso that when **B** is adenine, **Z** is **ORb**, **D**₁ is H, **D**₂ is H and **Rb** is H, **Ra** is not triphosphate or H.

2. A method according to claim 1 wherein **Z** is OH.
3. A method according to claim 2 wherein **D₁** is H and **D₂** is F.
4. A method according to claim 2 wherein **R_a** is chosen from H, monophosphate, diphosphate, triphosphate.
- 10 5. A method according to claim 2 wherein **R_a** is triphosphate.
6. A method according to claim 2 wherein **R_a** is H.
7. A method according to claim 3 wherein **R_a** is chosen from H, monophosphate, diphosphate, triphosphate.
8. A method according to claim 3 wherein **R_a** is triphosphate.
- 20 9. A method according to claim 3 wherein **R_a** is H.
10. A method according to claim 2 wherein **B** is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, 3-carboxamido-1,2,4-triazol-1-yl, 3-deaza-adenin-9-yl, 3-deaza-guanin-9-yl, 3-deaza-inosin-9-yl, 3-deaza-2-amino-purin-9-yl, 3-deaza-2-amino-6-chloro-purin-9-yl, 30 3-deaza-2-6-diamino-purin-9-yl, 7-deaza-adenin-9-yl, 7-deaza-guanin-9-yl, 7-deaza-inosin-9-yl, 7-deaza-2-amino-purin-9-yl, 7-deaza-2-amino-6-chloro-purin-9-yl, 7-deaza-2-6-diamino-purin-9-yl, 7-deaza-8-aza-adenin-9-yl, 7-deaza-8-aza-guanin-9-yl, 7-deaza-8-aza-inosin-9-yl, 7-deaza-8-aza-2-amino-purin-9-yl, 7-deaza-8-aza-2-

amino-6-chloro-purin-9-yl, 7-deaza-8-aza-2-6-diamino-purin-9-yl, 8-aza-adenin-9-yl, 8-aza-guanin-9-yl, 8-aza-inosin-9-yl, 8-aza-2-amino-purin-9-yl, 8-aza-2-amino-6-chloro-purin-9-yl, 8-aza-2-6-diamino-purin-9-yl, 5-aza-thymin-1-yl, 5-aza-cytosin-1-yl, 5-aza-uracil-1-yl, 6-aza-thymin-1-yl, 6-aza-cytosin-1-yl, 6-aza-uracil-1-yl; each of which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, -OC₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

10 11. A method according to claim 3 wherein B is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, uracil-1-yl, 3-carboxamido-1,2,4-triazol-1-yl, 3-deaza-adenin-9-yl, 3-deaza-guanin-9-yl, 3-deaza-inosin-9-yl, 3-deaza-2-amino-purin-9-yl, 3-deaza-2-amino-6-chloro-purin-9-yl 3-deaza-2-6-diamino-purin-9-yl, 7-deaza-adenin-9-yl, 7-deaza-guanin-9-yl, 7-deaza-inosin-9-yl, 7-deaza-2-amino-purin-9-yl, 7-deaza-2-amino-6-chloro-purin-9-yl, 7-deaza-2-6-diamino-purin-9-yl, 7-deaza-8-aza-guanin-9-yl, 7-deaza-8-aza-inosin-9-yl, 7-deaza-8-aza-2-amino-purin-9-yl, 7-deaza-8-aza-2-amino-6-chloro-purin-9-yl, 7-deaza-8-aza-2-6-diamino-purin-9-yl, 8-aza-adenin-9-yl, 8-aza-guanin-9-yl, 8-aza-inosin-9-yl, 8-aza-2-amino-purin-9-yl, 8-aza-2-6-diamino-purin-9-yl, 5-aza-thymin-1-yl, 5-aza-cytosin-1-yl, 5-aza-uracil-1-yl, 6-aza-thymin-1-yl, 6-aza-cytosin-1-yl, 6-aza-uracil-1-yl; each of which is unsubstituted or substituted by at least one of NHR₃, C₁₋₆alkyl, -OC₁₋₆alkyl, Br, Cl, F, I or OH, wherein R₃ is H, C₁₋₆alkyl or C₁₋₆acyl.

12. A method according to claim 2 wherein **B** is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, 5-fluoro-cytosin-1-yl, uracil-1-yl, 5-fluorouracil or 1,2,4-triazole-3-carboxamide base (ribarivin base).

13. A method according to claim 3 wherein **B** is chosen from adenin-9-yl, guanin-9-yl, inosin-9-yl, 2-amino-purin-9-yl, 2-amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, thymin-1-yl, cytosin-1-yl, 5-fluoro-cytosin-1-yl, uracil-1-yl, 5-fluorouracil or 1,2,4-triazole-3-carboxamide base (ribarivin base).

14. A method according to claim 1 wherein the compound of formula I is chosen from:

Compound #1:3'-deoxycytidine;

Compound #2: 3'-deoxycytidine-5' triphosphate;

20 Compound #3:5-Fluoro-3'-deoxycytidine;

Compound #4:5-Fluoro-3'-deoxycytidine-5' triphosphate;

Compound #5:3'-deoxyuridine;

Compound #6:3'-deoxyuridine-5' triphosphate;

Compound #7:5-Fluoro-3'-deoxyuridine;

Compound #8:5-Fluoro-3'-deoxyuridine-5' triphosphate;

Compound #9:3'-deoxythymidine;

Compound #10:3'-deoxythymidine-5' triphosphate;

Compound #11:3'-deoxyguanosine;

Compound #12:3'-deoxyguanosine-5' triphosphate;

30 Compound #13:2-N-acetyl-3'-deoxyguanosine;

Compound #14:2-N-acetyl-3'-deoxyguanosine-5' triphosphate;

Compound #15:5-Methyl-3'-deoxycytidine;

Compound #16:5-Methyl-3'-deoxycytidine-5' triphosphate;

Compound #17:5-Iodo-3'-deoxycytidine;

Compound #18:5-Iodo-3'-deoxycytidine-5' triphosphate;

Compound #19: 5-Chloro-3'-deoxycytidine;
Compound #20: 5-Chloro-3'-deoxycytidine-5' triphosphate;
Compound #21: 3'-fluoro-3'-deoxyguanosine;
Compound #22: 3'-fluoro-3'-deoxyguanosine -5' triphosphate;
Compound #23: 3'-fluoro 3'-deoxycytidine;
Compound #24: 3'-fluoro 3'-deoxycytidine-5' triphosphate;
Compound #25: 5-Iodo-3'-deoxycytidine;
Compound #26: 5-Iodo-3'-deoxycytidine-5' triphosphate;
Compound #27: 5-Chloro -3'-deoxyuridine;
10 Compound #28: 5-Chloro -3'-deoxyuridine-5' triphosphate;
Compound #29: 5-Bromo -3'-deoxyuridine;
Compound #30: 5-Bromo -3'-deoxyuridine-5' triphosphate;
Compound #31: 6-Chloro-3'-deoxyguanosine;
Compound #32: 6-Chloro -3'-deoxyguanosine -5' triphosphate;
Compound #33: 3'-spirocyclopropyl-3'-deoxyguanosine;
Compound #34: 3'-spirocyclopropyl-3'-deoxyguanosine -
5' triphosphate;
Compound #35: 3'-difluoro-spirocyclopropyl-3'-
deoxyguanosine;
20 Compound #36: 3'-difluoro-spirocyclopropyl-3'-
deoxyguanosine -5' triphosphate;
Compound #37: 3'-methylene-3'-deoxyguanosine;
Compound #38: 3'-methylene-3'-deoxyguanosine -
5' triphosphate;
Compound #39: 3'-difluromethylene 3'-deoxyguanosine;
Compound #40: 3'-difluromethylene 3'-deoxyguanosine -
5' triphosphate;
Compound #41: 3'-spirocyclopropyl-3'-deoxycytidine;
Compound #42: 3'-spirocyclopropyl-3'- deoxycytidine -
30 5' triphosphate;
Compound #43: 3'-difluoro-spirocyclopropyl-3'-
deoxycytidine;
Compound #44: 3'- difluoro-spirocyclopropyl-3'-
deoxycytidine -5' triphosphate;

- Compound #45: 3'-methylene-3'- deoxycytidine;
Compound #46: 3'-methylene-3'- deoxycytidine -
5' triphosphate;
Compound #47: 3'-difluoromethylene 3'- deoxycytidine;
Compound #48: 3'-difluoromethylene 3'- deoxycytidine -
5' triphosphate;
Compound #49: 9- β -D-xylofuranosyl-guanosine;
Compound #50: 9- β -D-xylofuranosyl-guanosine -
5' triphosphate;
- 10 Compound #51: 9- β -D-xylofuranosyl-cytidine;
Compound #52: 9- β -D-xylofuranosyl-cytidine -
5' triphosphate;
Compound #53: 3'-azido-3'- deoxycytidine;
Compound #54: 3'-azido-3'- deoxycytidine 5' triphosphate; or
a pharmaceutically acceptable salt thereof.
15. The method according to anyone of claims 1 to 14
wherein said compound is used in combination with at
least one further therapeutic agent chosen from
20 interferon (IFN), interferon α -2a, interferon α -2b,
consensus interferon (CIFN), ribavirin, amantadine,
rimantadine, interleukine-12, ursodeoxycholic acid
(UDCA), glycyrrhizin and silybum marianum.

16. Use of a compound of formula (Ib) as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a hepatitis C infection.
17. An anti-flavivirus pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (Ib), as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
18. Use of a compound of formula (Ib) as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a Flavivirus infection.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/060315 A3

(51) International Patent Classification⁷: **A61K 31/7068, 31/7072, 31/7076, 31/708, A61P 31/12**

(74) Agents: MURPHY, Kevin, P. Swabey Ogilvy Renault et al.; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(21) International Application Number: **PCT/CA01/00197**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 19 February 2001 (19.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/183,349 18 February 2000 (18.02.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ISMAILI, Hicham, Moulay, Alaoui [CA/CA]; 5059 Westmore, Montréal, Québec H4V 1Z4 (CA). CHENG, Yun-Xing [CA/CA]; 1 Davignon, Apt. 319, Dollard des Ormeaux, Québec H9B 2M4 (CA). LAVALLÉE, Jean-François [CA/CA]; 28 Chemin Scraire, Bellefeuille, Québec J0R 1A0 (CA). SIDDIQUI, Arshad [CA/CA]; 116 Stéphanie, Dollard des Ormeaux, Québec H9A 3B5 (CA). STORER, Richard [GB/CA]; 215 Oakridge, Baie d'Urfé, Québec H9X 2N3 (CA).**

Published:

— with international search report

(88) Date of publication of the international search report:
16 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/060315 A3

(54) Title: METHOD FOR THE TREATMENT OR PREVENTION OF *FLAVIVIRUS* INFECTIONS USING NUCLEOSIDE ANALOGUES

(57) Abstract: The present invention relates to a method for the treatment or prevention of Flavivirus including hepatitis C virus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having formula (I) or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

national Application No

PCT/CA 01/00197

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/7068 A61K31/7072 A61K31/7076 A61K31/708 A61P31/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, MEDLINE, EMBASE, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 705 522 A (HAMEDI-SANGSARI FARID ET AL) 6 January 1998 (1998-01-06) abstract column 3, line 22-48	1,2,4,6, 9-13, 16-18
X	RUTSCHMANN O T ET AL: "Impact of treatment with Human Immunodeficiency Virus (HIV) Protease Inhibitors on Hepatitis C viremia in Patients Coinfected with HIV" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 177, no. 3, 1 March 1998 (1998-03-01), pages 783-785, XP002095184 ISSN: 0022-1899 the whole document ---	1,15-18 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

3 June 2002

Date of mailing of the International search report

10/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5018 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

INTERNATIONAL SEARCH REPORT

National Application No

PCT/CA 01/00197

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 00 50064 A (TAN YIN HWEE ;INST OF MOLECUL & CELL BIOLOGY (SG); DRISCOLL JOHN S) 31 August 2000 (2000-08-31) abstract page 1, line 29 -page 2, line 24 page 5, line 25 -page 6, Line 6; table 1. page 17, line 15 -page 21, line 5; claims 1-21	1-9, 15-18
A	AHMED A ET AL: "TREATMENT STRATEGIES FOR CHRONIC HEPATITIS C: UPDATE SINCE THE 1997 NATIONAL INSTITUTES OF HEALTH CONSENSUS DEVELOPMENT CONFERENCE" JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, MELBOURNE, AU, vol. 14, May 1999 (1999-05), pages S12-S18, XP000872638 ISSN: 0815-9319 the whole document	1-18
A	BRILLANTI S ET AL: "PILOT STUDY OF TRIPLE ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN INTERFERON ALPHA NON-RESPONDERS" ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, PACINI EDITORE, PISA, IT, vol. 31, no. 2, March 1999 (1999-03), pages 130-134, XP000997994 ISSN: 1125-8055 the whole document	1-18
A	MIKHAILOPOLO I A ET AL: "SYNTHESIS AND ANTIVIRAL AND CYTOSTATIC PROPERTIES OF 3'-DEOXY-3'-FLUORO- AND 2'-AZIDO-3'-FLUORO-2',3'-DIDEOXY-D-RIBOFURANO SIDES OF NATURAL HETEROCYCLIC BASES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 34, 1991, pages 2195-2202, XP001077026 ISSN: 0022-2623 the whole document	1-18
A	AERSCHOT VAN A ET AL: "SYNTHESIS AND ANTIVIRAL ACTIVITY EVALUATION OF 3'-FLUORO-3'-DEOXYRIBONUCLEOSIDES: BROAD-SPECTRUM ANTIVIRAL ACTIVITY OF 3'-FLUORO-3'-DEOXYADENOSINE" ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, no. 12, 1989, pages 133-150, XP002908279 ISSN: 0166-3542 the whole document	1-18

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/00197

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LIN T-S ET AL: "SYNTHESIS AND ANTICANCER AND ANTI VIRAL ACTIVITIES OF VARIOUS 2'-AND 3'-METHYLDENE-SUBSTITUTED NUCLEOSIDE ANALOGUES AND CRYSTAL STRUCTURE OF 2'-DEOXY-2'-METHYLDENECYTIDINE HYDROCHLORIDE"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 8, no. 34, 1991, pages 2607-2615, XP001077025</p> <p>ISSN: 0022-2623 the whole document</p> <p>---</p>	1-18
A	<p>ROBINS M J ET AL: "NUCLEIC ACID RELATED COMPOUNDS. 74. SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2'(AND 3')-DEOXY-2'(AND 3')-METHYLENENUCLEOSIDE ANALOGUES THAT FUNCTION AS MECHANISM-BASED INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND/OR RIBONUCLEOTIDE REDUCTASE"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, 1992, pages 2283-2293, XP001077027</p> <p>ISSN: 0022-2623 the whole document</p> <p>---</p>	1-18

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-13,15-18 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables, that a lack of clarity (Cf. e.g. a purine, a pyrimidine or an analogue thereof, a hydroxy protecting group, ...) (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely all the individual compounds of claim 14 in relation to the prevention or treatment of a flavivirus infection and particularly hepatitis C infection.

Remark: Compounds 49-52 do not fall within the scope of formula Ib.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/CA 01/00197

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5705522	A	06-01-1998	AT AU DE EP WO JP	203513 T 6835096 A 69614127 D1 0854860 A1 9710205 A1 2000511871 T	15-08-2001 01-04-1997 30-08-2001 29-07-1998 20-03-1997 12-09-2000
WO 0050064	A	31-08-2000	AU EP WO	3501100 A 1154787 A2 0050064 A2	14-09-2000 21-11-2001 31-08-2000